Debbie Joyce Williams, CNS
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Debbie Joyce Williams’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence G930 · Cancelled
Licence status: Cancelled · since 1947 · Loma Linda University School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 13 Part D prescriptions in 2020. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2020 | 13 | None | 0% (0) | 0% | $652 |
| 2018 | 52 | 22 | None | None | $92,533 |
| 2017 | 160 | 45 | 15% (24) | None | $103,099 |
| 2016 | 228 | 65 | 8% (18) | 8% | $12,718 |
| 2015 | 269 | 87 | 9% (23) | None | $13,442 |
| 2014 | 97 | 49 | None | 12% | $10,846 |
| 2013 | 26 | None | 0% (0) | 0% | $565 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2018: 1 drug
| Anastrozole | 11 | $188 | $17 |
2017: 4 drugs
| Tamoxifen Citrate | 18 | $860 | $48 |
| Anastrozole | 35 | $568 | $16 |
| Morphine Sulfate Er | 12 | $266 | $22 |
| Alendronate | 11 | $37 | $3 |
2016: 5 drugs
| Exemestane | 20 | $6,720 | $336 |
| Anastrozole | 60 | $745 | $12 |
| Tamoxifen Citrate | 24 | $631 | $26 |
| Venlafaxine Hcl Er | 15 | $166 | $11 |
| Letrozole | 11 | $140 | $13 |
2015: 6 drugs
| Exemestane | 22 | $6,056 | $275 |
| Anastrozole | 55 | $750 | $14 |
| Tamoxifen Citrate | 23 | $663 | $29 |
| Venlafaxine Hcl Er | 28 | $230 | $8 |
| Pantoprazole | 12 | $158 | $13 |
| Letrozole | 12 | $122 | $10 |
Money from drug and device companies
$1,150 in 2025
| 2025 | 10 | 11 | None | $1,150 |
| 2024 | 8 | 15 | None | $978 |
| 2023 | 7 | 8 | None | $626 |
| 2022 | 4 | 5 | None | $406 |
| 2021 | 7 | 9 | None | $829 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Syndax Pharmaceuticals | Revuforj | $145 | 1 payment
|
| Coloplast | Luja Coude | $141 | 1 payment
|
| Astellas Pharma US | Padcev | $140 | 1 payment
|
| Daiichi Sankyo | Datroway | $135 | 1 payment
|
| Janssen Biotech | Rybrevant | $131 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Datroway | $118 | 1 payment
|
See all 11 published payments
| Abbvie | Meals · 2025-11-13 | Qulipta | $96 |
| Syndax Pharmaceuticals | Meals · 2025-11-03 | Revuforj | $145 |
| Incyte | Meals · 2025-10-16 | Jakafi | $117 |
| Lilly USA | Meals · 2025-10-09 | Zepbound | $103 |
| Daiichi Sankyo | Meals · 2025-10-08 | Datroway | $135 |
| Astellas Pharma US | Meals · 2025-09-16 | Padcev | $140 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-29 | Vonvendi | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Datroway | $118 |
| Janssen Biotech | Meals · 2025-05-29 | Darzalex | $16 |
| Janssen Biotech | Meals · 2025-05-13 | Rybrevant | $115 |
| Coloplast | Meals · 2025-01-20 | Luja Coude | $141 |
See earlier years (2024, 2023, 2022, 2021)
2024: $978
| AstraZeneca Pharmaceuticals LP | None | $241 | 2 payments
|
| Daiichi Sankyo | Enhertu | $228 | 2 payments
|
| Abbvie | Venclexta | $172 | 6 payments
|
| Gilead Sciences | None | $118 | 1 payment
|
| Exelixis | Cabometyx | $76 | 1 payment
|
| Stemline Therapeutics | Orserdu | $69 | 1 payment
|
| Janssen Biotech | Tecvayli | $49 | 1 payment
|
| Merck Sharp & Dohme | None | $25 | 1 payment
|
2023: $626
| Daiichi Sankyo | None | $236 | 2 payments
|
| Karyopharm Therapeutics | Xpovio | $125 | 1 payment
|
| Seagen | Padcev | $122 | 1 payment
|
| Gilead Sciences | Trodelvy | $99 | 1 payment
|
| Merck Sharp & Dohme | Prevymis | $16 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $15 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $13 | 1 payment
|
2022: $406
| AstraZeneca Pharmaceuticals LP | Calquence | $158 | 2 payments
|
| Kite Pharma | Yescarta | $100 | 1 payment
|
| Janssen Biotech | Darzalex | $76 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $72 | 1 payment
|
2021: $829
| Incyte | Jakafi | $228 | 2 payments
|
| GlaxoSmithKline | Blenrep | $227 | 2 payments
|
| Daiichi Sankyo | Enhertu | $124 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Calquence | $119 | 1 payment
|
| Exelixis | Cabometyx | $95 | 1 payment
|
| Genentech USA | Venclexta | $21 | 1 payment
|
| Boston Scientific | General Pain Management | $14 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1326320094
- Licence
- CA 930California G930: Cancelled
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-09-19
- NPI last updated
- 2023-02-20
- NPI record certified
- 2023-02-20
This is when the NPI record was last certified, not a medical board exam.